5:24 PM
 | 
Jan 08, 2013
 |  BC Extra  |  Clinical News

MDCO gains on Phase III data for cangrelor

The Medicines Co. (NASDAQ:MDCO) jumped $3.01 (12%) to $28.83 on Tuesday after reporting that IV cangrelor met the primary composite endpoint in the Phase III CHAMPION PHOENIX trial to prevent platelet activation and aggregation in patients undergoing percutaneous coronary intervention (PCI). Specifically, cangrelor followed by...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >